FORM 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION


Washington D.C. 20549

 

 

Report of Foreign Issuer

 

 

Pursuant to Rule 13a-16 or 15d-16 of


the Securities Exchange Act of 1934

 

 

 

For period ending 16 December 2016

 

GlaxoSmithKline plc

(Name of registrant)


 

 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)


 

 

 

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F


 

 

 

Form 20-F x     Form 40-F


 

--


 

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.


 

 

 

 

 

GlaxoSmithKline plc

(the 'Company')

 

Notification of Transfer of Shares out of Treasury

 

Pursuant to the Financial Conduct Authority's Listing Rule 12.6.4, the Company hereby notifies the market of the following:

 

On 15 December 2016, the Company transferred 33,300,000 ordinary shares of 25 pence each ('Ordinary Shares') that were held by the Company in treasury ('Treasury Shares') to the GlaxoSmithKline Employee Benefit Trust to be used specifically to satisfy awards granted under the Company's Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received was £15.07 pence per Ordinary Share.

 

Following the transfer, the Company's issued share capital consisted of 5,368,238,025 Ordinary Shares, of which 458,205,950 were held as Treasury Shares.

 

Therefore, the total number of voting rights in the Company is 4,910,032,075. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

 

V A Whyte

Company Secretary

 

16 December 2016

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.


	GlaxoSmithKline plc
	(Registrant)
Date: December 16, 2016
	By: VICTORIA WHYTE --------------------------
	Victoria Whyte
	Authorised Signatory for and on
	behalf of GlaxoSmithKline plc